According to TipRanks, Santangelo is a 5-star analyst with an average return of 15.6% and a 61.83% success rate.
Progyny has an analyst consensus of Strong Buy, with a price target consensus of $52.00, implying a 26.37% upside from current levels. In a report released on August 5, Berenberg Bank also reiterated a Buy rating on the stock with a $58.00 price target.
PGNY market cap is currently $3.78B and has a P/E ratio of 90.36.
Based on the recent corporate insider activity of 122 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PGNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY: